BeOne Medicines (BEIGF) Income from Non-Controlling Interests (2017 - 2020)

BeOne Medicines (BEIGF) has reported Income from Non-Controlling Interests for 4 consecutive years, with $96000.0 the latest figure, recorded in Q4 2020.

• On a quarterly basis, Income from Non-Controlling Interests fell 42.17% year-over-year to $96000.0 in Q4 2020; TTM through Sep 2021 was $96000.0, a 102.71% increase from a year earlier, with the FY2020 full-year figure at -$3.6 million, down 85.49% from the prior year.
• Income from Non-Controlling Interests was $96000.0 for Q4 2020 at BeOne Medicines, up from -$1.4 million in the prior quarter.
• Over five years, Income from Non-Controlling Interests peaked at $1.5 million in Q4 2018 and troughed at -$1.4 million in Q3 2020.
• A 4-year average of -$401666.7 and a median of -$429000.0 in 2019 frame the typical range for Income from Non-Controlling Interests.
• The widest YoY moves for Income from Non-Controlling Interests: up 3493.02% in 2018, down 513.33% in 2018.
• Over 4 years, Income from Non-Controlling Interests stood at $43000.0 in 2017, then jumped by 3493.02% to $1.5 million in 2018, then tumbled by 89.26% to $166000.0 in 2019, then slumped by 42.17% to $96000.0 in 2020.
• The last three Income from Non-Controlling Interests figures came in at $96000.0 (Q4 2020), -$1.4 million (Q3 2020), and -$1.1 million (Q2 2020), per Business Quant data.